-+ 0.00%
-+ 0.00%
-+ 0.00%

Evogene urges vote for board slate as dissidents seek wholesale replacement ahead of Sept. 4 meeting

PUBT·08/31/2026 12:04:14
Listen to the news
Evogene urges vote for board slate as dissidents seek wholesale replacement ahead of Sept. 4 meeting
  • Evogene urged shareholders to back its board nominees at the Sept. 4, 2026 annual meeting amid a dissident campaign.
  • Dissident shareholders L.I.A. Pure Capital, Invest-Pro pushed for a full board replacement.
  • Management argued a wholesale reset risks disruption, citing an 18-month overhaul centered on ChemPass AI and partnership-driven drug development.
  • Evogene highlighted a cut in expected 2026 cash burn to $8.5-$9.5 million from about $20.5 million in 2024.
  • Board refresh plan included adding Yael Margolin, Yoshinori Oikawa; dissidents criticized for not detailing an alternative strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN36913) on August 31, 2026, and is solely responsible for the information contained therein.